Pneumagen
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Kinburn Castle Doubledykes Rd, Saint And...Website
www.pneumagen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Pneumagen
NorthLinks Bio is a biotech company focused on developing innovative solutions in collaboration with RA Capital. The company has recently acquired Pneumagen as a subsidiary. They are currently preparing to launch their new website to provide more information about their products and services. Their intended clients include stakeholders in the biotechnology sector.Explore more
Pneumagen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pneumagen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Pneumagen launches new products
Check if Pneumagen has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Pneumagen recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Pneumagen
Check out if Pneumagen is spiking on competitors!
Pneumagen, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Pneumagen had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Pneumagen has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Pneumagen
Find 3 more new buyers
Compare Similar Companies to Pneumagen
Compare insights from companies similar to Pneumagen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Pneumagen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pneumagen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pneumagen.
Pneumagen financials insights
Gather financial insights about Pneumagen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$4.9M
2023
Other Financing Round
$10M
Pneumagen Tech Stack
A closer look at the technologies used by Pneumagen
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Funding
Executive Move
Board of Directors
Funding
Pneumagen News & Media
Pneumagen Announces Peer-Reviewed Publication of Positive Phase II Study Data Highlighting the Potential of Neumifil, a Novel Broad-Spectrum Antiviral
St Andrews, UK – 2 July 2025 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), announces the publication of its Phase II Proof of Concept, Controlled Human Infection Model (CHIM) study investigating the efficacy and safety of Neumifil in the peer-reviewed journal Infectious Diseases and Therapy.Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication
St Andrews, UK – 3 July 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), announces the publication of new preclinical data evaluating Neumifil in a wide range of viral disease models. These preclinical data are published in the peer-reviewed journal, Antiviral Research in a paper entitled, “HEX17(Neumifil): An intranasal respiratory biotherapePneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference
St Andrews, UK – 23nd May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), presented positive results from its Phase 2, proof-of-concept, Controlled Human Infection Model (CHIM) study in which healthy volunteers were challenged with influenza virus following administration of Neumifil. These data were featured during an oral presentation* at tPneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024
Data to be presented in oral and ePoster presentations
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pneumagen
Sign Up For FreeTo access detailed company insights
NorthLinks Bio is a biotech company focused on developing innovative solutions in collaboration with RA Capital. The company has recently acquired Pneumagen as a subsidiary. They are currently preparing to launch their new website to provide more information about their products and services. Their intended clients include stakeholders in the biote... Read More
